Edwards Lifesciences: a Profile of the Heart Tech Specialist

Edwards Lifesciences is a global leader in medical innovations around structural heart disease,
As Edwards Lifesciences agrees to sell its critical care products unit to Becton Dickinson, we profile Edwards' historical contribution to heart health

Edwards Lifesciences has agreed to sell its critical care products unit to Becton Dickinson, in a deal valued at $4.2 billion to sharpen focus on its heart devices business.

US-based Edwards Lifesciences is a global leader in medical innovations around structural heart disease, and it is this side of its business that it will now focus on.

Edwards’ Critical Care business develops and sells advanced blood and heart monitoring systems used in surgical and intensive care settings.

Here, we take a closer look at Edwards Lifesciences, its history, products and its influence on heart health.

Youtube Placeholder

Edwards Lifesciences: a pioneering force in heart health

Established in 1958 and headquartered in Irvine, California, Edwards Lifesciences is a global leader in the medical technology industry. The company’s focus has traditionally always been on innovative therapies for structural heart disease and critical care monitoring.

As the world's population ages and the prevalence of heart disease continues to rise, the company’s heart health technologies are becoming increasingly crucial. 

It was founded by Miles Edwards, an engineer and inventor who recognised the need for artificial heart valves. His pioneering work laid the foundation for Edwards Lifesciences' expertise in tissue replacement heart valves, which have become a cornerstone of the company's product portfolio.

One of Edwards Lifesciences' most significant contributions to heart health is the development of the first commercially available transcatheter heart valve. 

This groundbreaking technology allows doctors to replace a patient's diseased aortic heart valve without the need for open-heart surgery, providing a less invasive option for those considered too high-risk for traditional surgical procedures. The transcatheter heart valve is inserted through a small incision in the leg and guided into the heart using a catheter.

Edwards Lifesciences also offers a range of surgical heart valve repair therapies, critical care hemodynamic monitoring systems – devices that measure a patient's cardiovascular function, providing valuable data to healthcare professionals.

In 2017, it acquired Valtech Cardio, a company specialising in transcatheter mitral and tricuspid therapies, further strengthening its position in the structural heart disease market.

Today, it has over 14,000 employees worldwide, and it operates across 100 countries.


Featured Articles

Philips Future Health Index Report: AI to Cut Waiting Times

Healthcare technology leader Philips says virtual care and AI is turning in an effort to cope with demand in its Future Health Index Report 2024

HCLTech and Olympus Advance AI into the Healthcare Industry

Giants HCLTech and Olympus Corporation, have developed their partnership to utilise technology and AI to transform the healthcare industry.

Cancer Vaccines Breakthrough a Glimpse of Healthcare Future

As the UK's NHS becomes the first healthcare provider to launch a cancer vaccine testing programme, we explore this groundbreaking oncological treatment

Change Healthcare Cyberattack Fallout Continues

Health Insurance & Finance

McKinsey: National E-health Initiatives on the Rise

Technology & AI

London Hospitals Cyberattack Wreaks Healthcare Havoc

Technology & AI